Artificial Tears, Tear Lipids and Tear Film Dynamics

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-30

Study Completion Date

2024-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dry eye disease (DED) is pervasive with some reports estimating over 16 million adults diagnosed in the United States. Currently, artificial tears remain an integral part of managing dry eyes and are mainly used for symptomatic relief. Recent studies have shown there may be therapeutic benefits with regular use of lipid-based artificial tears to improve the structure of the tear film, which may improve tear film stability and provide relief of symptoms. In this study the investigators propose to compare effects on the tear lipid film and its dynamics between 3 lipid based artificial tears and a widely available non-lipid based artificial tear.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tear Lipid Layer Thickness With Emollient Eye Drops

NCT03380624

Dry Eye Syndromes

COMPLETED PHASE4

Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers

NCT01339936

Dry Eye Syndrome

COMPLETED PHASE2/PHASE3

Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

NCT01614847

Dry Eye

COMPLETED PHASE4

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

NCT00932477

Dry Eye Syndrome

COMPLETED NA

Efficacy of the Chronic Application of Tear Formulations

NCT01384851

Dry Eye

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, double-masked, randomized, controlled, parallel-group trial designed to compare the impact of Systane Complete PF lipid-based artificial tears (the Treatment solution under study) on tear lipid layer thickness compared with a non-lipid Control solution, Refresh Relieva PF. Secondarily, the study will compare changes in tear lipid layer thickness, lipid layer uniformity, tear film thinning dynamics, and symptoms between the Treatment solution, the non-lipid Control solution, and 2 other available lipid-based solutions (Active Comparators: Refresh Optive Mega-3 PF and CVS Health Lubricant Eye Drop (PG 0.6%)). The study will include 4 clinic visits, and require 1 week of single-masked run-in with Systane Ultra PF (an over-the-counter non-lipid-based solution) followed by 3 months of study treatment dosing. All subjects will complete a screening interview, then an in-clinic baseline ocular health examination and study eligibility determination followed by dispensing of the Control solution to all subjects for 1 week of run-in. After that week, subjects will be randomized to 1 of the 4 artificial tear solutions and have an in-clinic ocular examination and dispense of the assigned solution to use for 3 months. An in-clinic follow-up examination is completed after 1 month of study solution use, followed by a phone interview at 2 months, and a final in-clinic examination at 3 months post-dispensing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

After the 1-week initial period during which all subjects will use the run-in solution, subjects will be randomly assigned one of the 4 study solutions, and neither the subject nor the clinician researchers or technicians conducting examinations and taking measurements will be aware of which solution is assigned. All 4 solutions will be dispensed in color- and name-coded identical dispensing bottles prepared by study personnel not involved in collecting data.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Systane Complete PF (Treatment)

Masked subjects assigned to Arm 1 will use Systane Complete PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.

Group Type EXPERIMENTAL

Systane Complete PF

Intervention Type DRUG

3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product

Refresh Relieva PF (Control)

Masked subjects assigned to Arm 2 will use Refresh Relieva PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.

Group Type PLACEBO_COMPARATOR

Refresh Relieva PF

Intervention Type DRUG

3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product

Refresh Optive Mega-3 PF (Active Comparator 1)

Masked subjects assigned to Arm 3 will use Refresh Optive Mega-3 PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.

Group Type ACTIVE_COMPARATOR

Refresh Optive Mega-3 PF

Intervention Type DRUG

3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product

CVS Health Lubricant Eye Drop (PG 0.6%) (Active Comparator 2)

Masked subjects assigned to Arm 4 will use CVS Health Lubricant Eye Drop (PG 0.6%) artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.

Group Type ACTIVE_COMPARATOR

CVS Health Lubricant Eye Drop (PG 0.6%)

Intervention Type DRUG

3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Systane Complete PF

3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product

Intervention Type DRUG

Refresh Relieva PF

3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product

Intervention Type DRUG

Refresh Optive Mega-3 PF

3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product

Intervention Type DRUG

CVS Health Lubricant Eye Drop (PG 0.6%)

3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Best Corrected Visual Acuity of 20/30 or better;
* Experiencing Dry Eye symptoms (baseline OSDI score \>= 13);

Exclusion Criteria

* Currently experiencing active ocular inflammation or infection;
* Currently using topical eye medication (not including over-the-counter eyedrops);
* Having systemic health conditions or using prescription medications (including but not limited to isotretinoin derivatives) that could alter tear film physiology;
* Having a history of severe ocular trauma, ocular surgery, or diabetes;
* Being pregnant or breast feeding;
* Being a current contact lens wearer;
* Currently having a condition or being in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may otherwise significantly interfere with their participation in the study;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes